Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis

Immunopathological changes in response to the lymphocyte function-associated antigen 3 antagonist alefacept or TNFα blockade in PsA have also shown a significant reduction of synovial T cells and macrophages in parallel to the clinical response. 8 9 Interestingly, in rheumatoid arthritis patients treated with abatacept, a significant reduction of synovial IFN[GAMMA] messenger RNA was only observed in responders. 10 This is consistent with our results and points to IFN[GAMMA] as a potential T-cell marker of response to abatacept. [...]we report the first case of clinical and biological response to abatacept in a patient with refractory PsA.